Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) have earned an average rating of “Moderate Buy” from the eight ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $56.35.

ZLAB has been the subject of a number of analyst reports. Jefferies Financial Group began coverage on Zai Lab in a research note on Monday, August 25th. They set a “buy” rating and a $52.00 price objective for the company. Citigroup reaffirmed a “buy” rating and issued a $69.00 price target (up from $66.00) on shares of Zai Lab in a research note on Monday, August 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zai Lab in a research note on Wednesday, October 8th.

Insider Transactions at Zai Lab

In other news, CFO Yajing Chen sold 1,438 shares of the business’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $35.42, for a total value of $50,933.96. Following the completion of the transaction, the chief financial officer owned 16,720 shares of the company’s stock, valued at $592,222.40. The trade was a 7.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Ying Du sold 50,000 shares of the company’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $34.64, for a total transaction of $1,732,000.00. Following the completion of the sale, the chief executive officer owned 536,962 shares of the company’s stock, valued at approximately $18,600,363.68. This represents a 8.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 104,706 shares of company stock valued at $3,675,390 over the last three months. 4.96% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zai Lab

Hedge funds have recently modified their holdings of the business. Kingsview Wealth Management LLC lifted its holdings in shares of Zai Lab by 6.0% during the 1st quarter. Kingsview Wealth Management LLC now owns 9,323 shares of the company’s stock valued at $337,000 after purchasing an additional 529 shares in the last quarter. Walleye Capital LLC lifted its stake in Zai Lab by 6.4% in the first quarter. Walleye Capital LLC now owns 22,276 shares of the company’s stock valued at $805,000 after buying an additional 1,338 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Zai Lab by 13.4% in the first quarter. China Universal Asset Management Co. Ltd. now owns 12,544 shares of the company’s stock valued at $453,000 after buying an additional 1,483 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of Zai Lab during the first quarter worth $75,000. Finally, Advisors Preferred LLC bought a new stake in shares of Zai Lab during the first quarter worth $110,000. Institutional investors and hedge funds own 41.65% of the company’s stock.

Zai Lab Price Performance

ZLAB opened at $21.90 on Friday. The firm has a 50 day simple moving average of $30.20 and a 200 day simple moving average of $33.03. Zai Lab has a fifty-two week low of $21.51 and a fifty-two week high of $44.34. The company has a market cap of $2.45 billion, a price-to-earnings ratio of -10.74 and a beta of 1.07.

Zai Lab (NASDAQ:ZLAB) last released its earnings results on Thursday, November 6th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). The business had revenue of $116.10 million for the quarter, compared to analyst estimates of $150.24 million. Zai Lab had a negative return on equity of 27.32% and a negative net margin of 49.68%. Zai Lab has set its FY 2025 guidance at EPS. As a group, analysts expect that Zai Lab will post -2.58 EPS for the current year.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.